MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517092157 A) filed by Merck Sharp & Dohme Llc; and Merck Sharp & Dohme (UK) Limited, Rahway, U.S.A., on Sept. 25, for 'controlled release pde10a formulations.'
Inventor(s) include Dinunzio, James C.; Harris, David; Kumar, Maria Sharlini; Pollitt, Michael John; Radojevic, Jovana; and Terife, Graciela.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates generally to treatment of central nervous system disorders associated with phosphodiesterase 10A (PDE10A) such as schizophrenia, bipolar disease, and Alzheimer's disease, as therapeutics for neurological and psychiatric disorders. This disclosure provides controlled-release formulations of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine (Compound A) and their use in the treatment of schizophrenia and other psychiatric disorders that improves the tolerability profile."
The patent application was internationally filed on Mar. 25, 2024, under International application No.PCT/US2024/021265.
Disclaimer: Curated by HT Syndication.
